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Abstract: The use of cardiac imaging modalities has grown steadily, and cardiac nuclear studies constitute a large part of 
this number. Nuclear Cardiology is often mistakenly considered a synonym of myocardial perfusion imaging (MPI), but 
has broader applications, including metabolic imaging, innervation imaging, among other technologies. MPI has been a 
powerful diagnostic and prognostic tool in the assessment of patients for known or suspected CAD for decades, and is 
now increasingly used for the evaluation of the anti-ischemic effects of various therapies, according to changes in left 
ventricular perfusion defect size defined by sequential MPI. Neuronal dysfunction identified with iodine-123-
metaiodobenzylguanidine may give information on prognosis in different disease conditions, such as after myocardial 
infarction, in diabetes and dilated cardiomyopathy. Molecular imaging may identify the predominant cellular population 
in the atherosclerotic plaque and help predict the likelihood of clinical events. Therefore, although its usefulness is well 
established, Nuclear Cardiology remains a moving science, whose roles keep in pace with evolving clinical needs and 
expectations.  
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  In association with the elevated prevalence, morbidity 
and mortality of coronary artery disease (CAD) worldwide, 
there has been a steady increase in the use of cardiac imaging 
techniques, including those based on Nuclear Medicine. In 
fact, cardiac studies have outgrown Nuclear Medicine and 
have constituted an individual subspecialty, Nuclear Cardio-
logy. This imaging modality is often, although incorrectly, 
considered as a synonym for myocardial perfusion imaging 
(MPI), which by its turn means the evaluation of myocardial 
perfusion after stress versus at rest, using a variety of tracers 
and stressor agents in different protocols. It extends far 
beyond, though, including metabolic imaging, innervation 
imaging, among other technologies. This review will discuss 
current and evolving applications of Nuclear Cardiology, 
starting with MPI, which remains its cornerstone. 
MYOCARDIAL PERFUSION IMAGING 
  For the last 2 decades, MPI has been an essential part of 
the diagnostic and prognostic assessment of patients for 
known or suspected CAD. However, as time went by and 
new demands and technologies have been developed, other 
applications of MPI have emerged, and its roles have 
advanced continuously. In the 1980’s, planar and then 
tomographic (single photon emission computed tomography, 
SPECT) perfusion imaging was found to reliably diagnose 
CAD [1,2]. In the 1990’s the prognostic value of MPI was 
defined [3-5]. Later, with the advent of gating, left ventri-
cular ejection fraction could be obtained, thus providing 
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Diagnostic Assessment 
  MPI is a useful tool for the diagnosis of CAD [1,2]. It is 
most effective when used in patients with an intermediate 
pretest likelihood of CAD, since if the likelihood is low, a 
perfusion abnormality may be a false-positive finding, while 
in those with a high pretest likelihood of CAD a normal MPI 
study may be a false-negative for the presence of angio-
graphically significant coronary obstruction (i.e., coronary 
stenoses > 50% of luminal diameter) and the test may not 
able to exclude the presence of CAD. Nonetheless, even in 
patients with high likelihood of CAD, MPI can still be used 
for risk stratification [8]. In fact, the principles regarding 
diagnostic applications of MPI have not changed over the 
years, in contrast to the prognostic use of MPI, which has 
grown significantly. 
Prognostic Assessment 
  MPI may be applied for prognostic evaluation both for 
patients with known or suspected CAD. It relies on 2 
principles: first, a normal MPI study confers a low (<1%) 
short-term risk of cardiac events [9]; second, there is a 
relationship between myocardial ischemia and cardiac events 
such that the risk of events increases exponentially as 
ischemia increases. Even in patients with a high likelihood of 
CAD or definite CAD, a normal MPI defines those who have 
a < 1% risk of cardiac events in the next 1-2 years. This 
usually defines a group in which conservative management 
(i.e., avoiding myocardial revascularization) is appropriate 
[10]. When some conditions are present, like diabetes, 
inability to exercise leading to the use of pharmacologic 
stress, abnormal rest ECG or exercise-induced ST segment 
depression, a normal MPI study still delineates low risk, but 
somewhat increased compared with patients with normal 
MPI and none of those [11,12]. For patients with abnormal 
studies, the risk of events is associated with the magnitude of 
ischemia. The latter is the strongest determinant of the 
referral to coronary angiography and also the strongest 
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a number of other findings obtained from MPI studies, such 
as abnormal lung uptake or transient left ventricular 
dilatation, have consistently been associated with increased 
risk [14, 15]. 
Therapeutic Assessment/MPI as a “Gatekeeper”  
  An increasingly used application of Nuclear Cardiology 
is to evaluate the anti-ischemic effects of various therapies 
by means of identifying changes in left ventricular perfusion 
defect size by sequential MPI and thereby track patient risk 
for subsequent cardiac events on the basis of the magnitude 
of ischemia suppression. An example is the COURAGE 
(Clinical Outcomes Utilizing Revascularization and Aggre-
ssive Drug Evaluation) trial [16], which evaluated percu-
taneous coronary intervention (PCI) plus optimal medical 
therapy (OMT) vs. OMT alone in stable CAD patients. A 
subgroup of the total population had MPI performed before 
and after treatment (mean 1 year after enrollment), and in 
this nuclear substudy, the results showed that ischemia 
reduction was greater with PCI+OMT than with OMT alone 
(33.3% versus 19.8% had 5% reduction of ischemia). For 
all patients combined, the death or myocardial infarction rate 
was 13.4% for patients who had 5% reduction of ischemia 
and 24.7% for those who did not have reduction at the 
follow-up study. This study indicated that, for stable CAD 
patients, having knowledge of the ischemic burden is helpful 
in decision-making with respect to selecting initial therapy, 
and regardless of the therapeutic modality used, assessment 
of the response to therapy, which is related to long-term 
outcome, is also important. Another aspect of this same 
application of MPI is the identification of revascularization 
candidates according to the amount of jeopardized myo-
cardium and the survival benefit that a patient may obtain 
from a specific therapy as a function of MPI results. MPI has 
been able to discriminate (as a “gatekeeper”) which patients 
will likely benefit from invasive coronary angiography 
followed by coronary revascularization and who may be well 
suited with medical therapy [13]. Quantitative analysis of 
MPI studies has been important in this regard, since this kind 
of analysis relies on the demonstration of a threshold value 
of ischemia which will lead to each type of management.  
Screening Asymptomatic Populations for CAD 
  The noninvasive detection of silent CAD is an important 
clinical goal in certain high-risk asymptomatic populations. 
Occult CAD precedes the onset of clinically manifest CAD, 
which too often presents as sudden death or acute myocardial 
infarction. Detection of occult CAD in a preclinical stage 
might lead to risk factor modification and institution of 
treatment, which would prevent or delay the onset of clinical 
disease, since there is now good evidence that aggressive 
risk factor modification can slow the progression of athero-
sclerosis. Bayesian analysis indicates that the detection of 
occult CAD by noninvasive testing should be more accurate 
in asymptomatic groups with high CAD prevalence, since 
test performance is worse in low prevalence populations 
[17]. As a result, screening is not considered appropriate for 
the general population, given the sensitivity and specificity 
of even the best noninvasive test. Screening seems more 
suitable for selected, high risk groups, such as patients with  
 
chronic renal failure, metabolic syndrome, and diabetics; in 
the latter, several studies have demonstrated a high 
prevalence of silent CAD detected with MPI [18, 19].  
Myocardial Viability 
  Noninvasive imaging to determine the presence and 
extent of dysfunctional but viable myocardium has become 
an important component of the diagnostic assessment of 
patients with CAD and depressed left ventricular function. It 
is now well established that left ventricular dysfunction in 
patients with CAD is not always an irreversible process 
related to previous myocardial infarction because left ventri-
cular function may improve substantially after revas-
cularization procedures in patients with chronic CAD, and 
this may translate into an improvement in survival [20]. The 
differentiation of viable from nonviable myocardium is 
highly relevant in patients with left ventricular dysfunction 
considered for revascularization, because these procedures 
often have high morbidity and mortality rates in this subset 
of patients, even though this is the population that ultimately 
benefits most from revascularization. Therefore, accurate 
methods to detect viable myocardium are essential to select 
the patients for whom the risks are justified. Nuclear 
Cardiology techniques to assess viability have evolved 
tremendously in recent years. In SPECT, there are various 
imaging protocols, the most frequently used being the 
thallium-201 protocols (rest/redistribution and reinjection 
studies) [21, 22]. According to the hypothesis of resting hyp-
operfusion (hibernation), rest images demonstrate thallium 
uptake early after injection, which represent regional 
myocardial blood flow, whereas delayed uptake reflects cell 
membrane integrity. Since 3-4 hour redistri-bution images 
may underestimate the presence of viable myocardium, 
reinjection of thallium at rest after redis-tribution imaging 
may improve the assessment of myocardial ischemia and 
viability in up to 49% of apparently irreversible defects [22]. 
As technetium-99m tracers are widely used due to favorable 
imaging properties compared to thallium, the use of these 
tracers for the assessment of viability has been studied, and 
quantitative measures of regional technetium-99m sestamibi 
activity have been shown to correlate with estimates of 
viability with other techniques [23]. Glucose metabolism 
assessment with F-18 fluorodeoxi-glucose (FDG) positron 
emission tomography (PET) also allows the identification of 
viable myocardium, with higher sensitivity; a perfusion-
metabolism mismatch (reduced blood flow associated with 
preserved or enhanced FDG uptake) identifies potentially 
reversible myocardial dysfunction [24]. 
MYOCARDIAL INNERVATION IMAGING 
    Iodine-123-metaiodobenzylguanidine (MIBG) was first 
reported as a potential neuronal imaging agent for detection 
of pheocromocytoma, since it has structural similarity with 
norepinephrine and therefore is taken up by peripheral 
sympathetic nerves. Further studies have shown reduced 
localization in denervated regions of the myocardium, after 
myocardial infarction, in diabetes and dilated cardiomyo-
pathy, among other conditions [25, 26]. MIBG imaging 
evaluates the sympathetic nervous system and has been 
shown to be an important prognosticator in patients with 
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POSITRON EMISSION TOMOGRAPHY (PET) 
  The lack of widespread availability of PET cameras and 
radiotracers, their high costs and reimbursement issues have 
limited the clinical use of this technology. Recent 
developments are likely to change this scenario, though, 
since there has been a growth in the number of PET cameras 
and rubidium-82 generators used for perfusion imaging. This 
leads to real benefit, since positron emission tomography 
(PET) has several technical advantages over SPECT, 
including higher spatial resolution, accurate attenuation corr-
ection, higher temporal resolution and quantitative imaging 
capability that afford measurement of rapidly changing 
radiotracer activity concentrations in blood and myocardium. 
All of those determine a clinical advantage over SPECT, 
which often uncovers only the territory supplied by the most 
severe stenosis and therefore may underestimate the 
significance of coronary lesions; in this regard, PET has 
superior capability to detect multivessel CAD [28,29].  
THE ASSOCIATION WITH COMPUTED TOMO-
GRAPHY: SPECT-CT/ PET-CT 
  Computed tomography of the coronary arteries (CTA) 
has gained enormous popularity in a short time period, and 
has been taken by some as a “threat” for Nuclear Cardiology. 
CTA and MPI differ in what each evaluates- anatomy for 
one and physiology for the other. Hybrid systems are now 
available allowing the combined assessment of anatomy and 
function, linking the anatomic richness of CTA and the 
functional importance of perfusion either from PET or 
SPECT. MPI and CTA are most likely complementary imag-
ing modalities, with the choice and sequence of testing 
depending on the particular clinical question and specific 
patient population being evaluated [30, 31].  
FATTY ACID IMAGING 
  BMIPP is a fatty acid analog which allows metabolic 
imaging since most of the energy requirement of the normal 
myocardium under aerobic status is derived from the 
metabolism of fatty acids. Since under ischemia or in heart 
failure, beta-oxidation of fatty acids in mitochondria is 
reduced, early washout of BMIPP from the myocardium 
occurs and the uptake detected by SPECT is reduced. 
BMIPP imaging may be used in unstable angina, vasospastic 
angina and cardiomyopathies, among other indications 
[32,33]. In particular, BMIPP metabolic imaging may be 
used to reveal “ischemic memory”, since even after 
resolution of chest pain, metabolic abnormalities may persist, 
and BMIPP images may be abnormal, with sensitivity of 
~70-80% and specificity of ~90% [34]. 
MOLECULAR IMAGING/PLAQUE IMAGING 
  The management of CAD has almost always been based 
on demonstration of the severity of luminal stenosis; such an 
approach, however, does not characterize the plaque mor-
phology that happens to be the major determinant of clinical 
outcome [35,36]. Appropriate targeting strategies with radio-
nuclide imaging techniques may identify the predominant 
cellular population in the atherosclerotic plaque and help 
predict the likelihood of clinical events. It is now well 
recognized that progressive luminal stenosis of the coronary 
artery is generally not associated with an acute event and that 
thrombotic occlusion usually occurs as a result of plaque 
rupture [37, 38]. The plaques that are vulnerable to rupture 
have large lipid cores, attenuated fibrous cap and intense 
infiltration of macrophages, which release metallopro-
teinases that digest matrix and induce fibrous cap rupture. 
Plaque rupture exposes thrombogenic lipid core leading to 
thrombotic luminal obstruction. Plaque imaging in Nuclear 
Cardiology has targeted most often macrophages or lipid 
cores. However, the uptake of radiolabeled antibodies or 
cells in the atherosclerotic lesion is a small fraction of the 
injected dose, what makes the background radioactivity a 
major contributor to the image and decreases the contrast 
between lesion and nonlesion tissue. The difficulty in 
identifying lesions in vivo is a problem and highlights the 
difficulty in the use of this innovative technique. In the 
carotids, F-18 FDG has been studied for plaque 
inflammation and technetium-99m-annexin SPECT has been 
evaluated for apoptosis within the plaque, both known 
markers of plaque instability [39,40].  
CONCLUSION 
  Although initially applied for diagnostic purposes, 
Nuclear Cardiology has grown and keeps moving. Many 
advances have increased its applications, and many more, 
regarding novel instrumentation techniques and new tracers 
are on their way to clinical practice. Perhaps the greatest 
potential for the future of Nuclear Cardiology lies in 
molecular imaging, and Nuclear Cardiology may hopefully 
achieve one of the most difficult goals in Cardiology: to 
identify the vulnerable, rupture-prone coronary plaque.  
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